An HPLC/MS/MS assay for tacrolimus in patient blood samples Correlation with results of an ELISA assay

https://doi.org/10.1016/S0731-7085(96)01951-6Get rights and content

Abstract

An HPLC/MS/MS assay for tacrolimus in whole blood using FR900520 as an internal standard was validated over the standard curve range of 0.100–10.040 ng ml−1. The calibration curve for tacrolimus in human blood gave a slope of 0.2481, an intercept of 0.007, and a correlation coefficient (r) of 0.9996, with no interference noted from human blood, analyte, or internal standard stock solutions. Use of EDTA or heparin as the preservative in blood resulted in no significant differences. Samples were stable for at least the time required to assay the maximum number of samples that could be placed in the automated system. The limit of sensitivity of the assay was set at the concentration of the lowest nonzero standard tested, i.e., 0.100 ng ml−1. However, validation of the assay to a limit of 0.010 ng ml−1 is currently underway. The within-run and between-run precision and accuracy of the method were determined for four quality control samples. The highest CV was seen at 0.1 ng ml−1 (17.6% within-run and 15.9% between-run), with other CV < 5%. The recovery ranged 79.6–81.3% for tacrolimus over the range 0.3–8.0 ng ml−1 and was 63.10 ± 1.37% for FR900520. There was a linear correlation (r2 = 0.963) between assay results by HPLC/MS/MS and ELISA in whole blood from atopic dermatitis patients treated with topical tacrolimus ointment. The difference between the means ± S.D. determined by HPLC/MS/MS (1.22 ± 1.46 ng ml−1) and ELISA (1.12 ± 1.29 ng ml−1) was significant by a paired t-test (P < 0.001). Similarly, there was a linear correlation (r2 = 0.841) between assay results by HPLC/MS/MS and IMx in whole blood from solid organ transplant patients treated with tacrolimus. The difference between the means was significantly higher (P < 0.001) for the IMx (15.80 ± 8.37 ng ml−1) than the HPLC/MS/MS (13.42 ± 6.87 ng ml−1).

References (16)

  • T. Goto et al.
  • T. Goto et al.
  • K. Abu-Elmagd et al.
  • K. Abu-Elmagd et al.
  • W.J. Jusko et al.

    Ther. Drug Monit.

    (1995)
  • W.J. Jusko

    Ther. Drug Monit.

    (1995)
  • P. McMaster et al.

    Ther. Drug Monit.

    (1995)
  • M. Winkler et al.

    Ther. Drug Monit.

    (1994)
There are more references available in the full text version of this article.

Cited by (47)

  • In vitro selection of tacrolimus binding aptamer by systematic evolution of ligands by exponential enrichment method for the development of a fluorescent aptasensor for sensitive detection of tacrolimus

    2020, Journal of Pharmaceutical and Biomedical Analysis
    Citation Excerpt :

    So far, various approaches have been reported for the quantitative detection of TAC [5], such as enzyme-linked immunosorbent assay (ELISA) [7–11] in which the mechanism of detection is based on the recognition of the metabolites of target instead of real target, itself. However, analytical approaches, such as HPLC-MS and HPLC-MS/MS are based on real targets detection rather than their metabolites [12,13]. Although these approaches are appropriate for TDM but they are time-consuming and need expensive equipment and skilled person.

  • Application of volumetric absorptive microsampling device for quantification of tacrolimus in human blood as a model drug of high blood cell partition

    2017, Journal of Pharmaceutical and Biomedical Analysis
    Citation Excerpt :

    As typical concentration levels in therapeutic drug monitoring samples were 3–15 ng/mL [14], a sensitive assay method is required, which is a challenge using a small volume of matrix in microsampling. A number of bioanalytical methods have been reported for the determination of tacrolimus in human blood [15–17] and assay methods in DBS have been reported as well [18–20]. We have established a reproducible bioanalytical method for tacrolimus on VAMS with the lower limit of quantification (LLOQ) of 1 ng/mL using only 0.01 mL blood samples.

  • Therapeutic drug monitoring of tacrolimus by liquid chromatography-tandem mass spectrometry: Is it truly a routine test?

    2012, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
    Citation Excerpt :

    There have been several recent reviews on the use of LC–MS/MS for the monitoring of tacrolimus and the other immunosuppressants in this class of drugs [14–17]. The early tacrolimus LC–MS/MS methods, as published by our group and others, had extensive sample preparation; with protein precipitation followed by off-line solid phase extraction or liquid-liquid extraction [18–20]. These methods were developed to encompass a wide analytical range (typically, 0.2–100 μg/L) as, at the time, knowledge of tacrolimus therapeutic ranges were still evolving.

  • Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations

    2011, Journal of Heart and Lung Transplantation
    Citation Excerpt :

    Whole-blood tacrolimus concentrations were determined by Covance Laboratories (Harrogate, UK; Madison, WI) using validated high-performance liquid chromatography tandem mass spectroscopy (HPLC/MS/MS) assay methods (lower limit of quantification, 0.059 ng/ml). The assay was based on the method developed by Alak et al.6 Whole-blood calibration standards, quality control samples, and study samples were thawed, and 1-ml aliquots were taken.

  • Determination of tacrolimus in rabbit aqueous humor by liquid chromatography-electrospray ionization tandem mass spectrometry

    2008, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
View all citing articles on Scopus
View full text